PBAC advises biosimilar medicines suitable for substitution at pharmacy level – June 2, 2015

In late April, 2015, The Pharmaceutical Benefits Advisory Committee (PBAC) pledged to consider marking biosimilar medicines equivalent to originator medicines, to which they are referenced against in Australia. This process would involve “a flagging”, whereby the biosimilar would be compared to the originator, in order to identify any significant differences in clinical efficacy or safety.…

Read More

7.9 month improvement in metastatic bowel cancer patients following microsphere radiotherapy and chemotherapy – June 2, 2015

As published on Bowel Cancer Australia’s website today, results from an Australian-led global study have shown that treatment with radiation microspheres and chemotherapy (chemo-radiotherapy) improved progression-free survival in the liver by around eight months among metastatic bowel cancer patients. The SIRFLOX study – the world’s largest study of its kind involving 530 metastatic bowel cancer patients…

Read More

Fatal lung infection not on public’s radar – May 19, 2015

Fatal lung infection not on public’s radar Experts calling for Aussie adults to curtail risk of infection this Pneumonia Awareness Week Fewer than one-in-seven Australian adults at-risk of pneumonia consider themselves vulnerable, with only one-in-five having reported vaccinating against the often-fatal lung infection.1 In addition to advancing age (65+), Lung Foundation Australia’s ‘Lungs4Life’ research released…

Read More

2015 Motor Neurone Disease (MND) Week – May 8, 2015

This week marks national Motor Neurone Disease (MND) Week in Australia, which runs from May 3 – 9 each year. National MND Week aims to acknowledge the MND community, including people living with MND, and commemorates Australian MND advocates and those who have passed away from the disease. Partnering with the State MND Associations, to…

Read More